414 related articles for article (PubMed ID: 32184342)
21. C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD.
Pache F; Ringelstein M; Aktas O; Kleiter I; Jarius S; Siebert N; Bellmann-Strobl J; Paul F; Ruprecht K
J Neuroimmunol; 2021 Nov; 360():577699. PubMed ID: 34464830
[TBL] [Abstract][Full Text] [Related]
22. The influence of smoking on the pattern of disability and relapse risk in AQP4-positive Neuromyelitis Optica Spectrum Disorder, MOG-Ab Disease and Multiple Sclerosis.
Messina S; Mariano R; Geraldes R; Kim SH; Satukijcha C; Vecchio D; Chua YY; Taylor J; George N; Cavey A; Diaz AR; Reeve S; Everett R; De Luca G; Leite MI; Kim HJ; Palace J
Mult Scler Relat Disord; 2021 Apr; 49():102773. PubMed ID: 33540279
[TBL] [Abstract][Full Text] [Related]
23. Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review.
Schindler P; Aktas O; Ringelstein M; Wildemann B; Jarius S; Paul F; Ruprecht K
Expert Rev Clin Immunol; 2023 Jan; 19(1):71-91. PubMed ID: 36378751
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of clinical and imaging data between patients with myelin oligodendrocyte glycoprotein antibody disease and patients with aquaporin 4 antibody-positive neuromyelitis optica spectrum disorder.
Xie H; Shao Y; Du J; Song Y; Li Y; Duan R; Yao Y; Gong Z; Teng J; Jia Y
J Neurol; 2022 Mar; 269(3):1641-1650. PubMed ID: 34383114
[TBL] [Abstract][Full Text] [Related]
25. Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease.
Akaishi T; Misu T; Fujihara K; Takahashi T; Takai Y; Nishiyama S; Kaneko K; Fujimori J; Ishii T; Aoki M; Nakashima I
J Neurol; 2022 Jun; 269(6):3136-3146. PubMed ID: 34820735
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-33 as a Biomarker Affecting Intrathecal Synthesis of Immunoglobulin in Neuromyelitis Optica Spectrum Disorder and Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.
Wang M; Xia D; Sun L; Bi J; Xie K; Wang P
Eur Neurol; 2023; 86(4):256-262. PubMed ID: 37100033
[TBL] [Abstract][Full Text] [Related]
27. CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage.
Hyun JW; Kim Y; Kim KH; Kim SH; Olesen MN; Asgari N; Siritho S; Paul F; Kim HJ
J Neuroinflammation; 2022 Apr; 19(1):86. PubMed ID: 35413922
[TBL] [Abstract][Full Text] [Related]
28. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
[TBL] [Abstract][Full Text] [Related]
29. Blood sphingolipid as a novel biomarker in patients with neuromyelitis optica spectrum disorder.
Kim H; Kim HJ; So J; Kim JY; Jung HJ; Kim S; Seo D; Kim HJ; Song HE; Lim YM; Yoo HJ; Lee EJ
Mult Scler Relat Disord; 2024 May; 85():105551. PubMed ID: 38564996
[TBL] [Abstract][Full Text] [Related]
30. Comparison of clinical characteristics and prognoses in patients with different AQP4-Ab and MOG-Ab serostatus with neuromyelitis optica spectrum disorders.
Du Q; Shi Z; Chen H; Zhang Y; Wang J; Qiu Y; Zhao Z; Zhang Q; Zhou H
J Neuroimmunol; 2021 Apr; 353():577494. PubMed ID: 33515897
[TBL] [Abstract][Full Text] [Related]
31. Neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated disease: current topics.
Fujihara K; Cook LJ
Curr Opin Neurol; 2020 Jun; 33(3):300-308. PubMed ID: 32374571
[TBL] [Abstract][Full Text] [Related]
32. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
[TBL] [Abstract][Full Text] [Related]
33. Evidence for and against subclinical disease activity and progressive disease in MOG antibody disease and neuromyelitis optica spectrum disorder.
Molazadeh N; Filippatou AG; Vasileiou ES; Levy M; Sotirchos ES
J Neuroimmunol; 2021 Nov; 360():577702. PubMed ID: 34547512
[TBL] [Abstract][Full Text] [Related]
34. Myelin oligodendrocyte glycoprotein antibodies in neuromyelitis optica spectrum disorder.
Ungureanu A; de Seze J; Ahle G; Sellal F
Rev Neurol (Paris); 2018 Dec; 174(10):675-679. PubMed ID: 30293882
[TBL] [Abstract][Full Text] [Related]
35. Serum level of IL-1β in patients with inflammatory demyelinating disease: Marked upregulation in the early acute phase of MOG antibody associated disease (MOGAD).
Kwon YN; Kim B; Ahn S; Seo J; Kim SB; Yoon SS; Sung JJ; Choi YS; Kim SM
J Neuroimmunol; 2020 Nov; 348():577361. PubMed ID: 32919144
[TBL] [Abstract][Full Text] [Related]
36. Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD.
Schroeder-Castagno M; Del Rio-Serrato A; Wilhelm A; Romero-Suárez S; Schindler P; Alvarez-González C; Duchow AS; Bellmann-Strobl J; Ruprecht K; Hastermann M; Grütz G; Wildemann B; Jarius S; Schmitz-Hübsch T; Paul F; Infante-Duarte C
J Neuroinflammation; 2022 Oct; 19(1):239. PubMed ID: 36183103
[TBL] [Abstract][Full Text] [Related]
37. Myelin Oligodendrocyte Glycoprotein-Immunoglobulin G in the CSF: Clinical Implication of Testing and Association With Disability.
Kwon YN; Kim B; Kim JS; Mo H; Choi K; Oh SI; Kim JE; Nam TS; Sohn EH; Heo SH; Kim SB; Park KC; Yoon SS; Oh J; Baek SH; Kim BJ; Park KS; Sung JJ; Jung JH; Kim SJ; Park SH; Waters P; Kim SM
Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34711644
[TBL] [Abstract][Full Text] [Related]
38. Myelin-oligodendrocyte glycoprotein antibody-associated disease.
Marignier R; Hacohen Y; Cobo-Calvo A; Pröbstel AK; Aktas O; Alexopoulos H; Amato MP; Asgari N; Banwell B; Bennett J; Brilot F; Capobianco M; Chitnis T; Ciccarelli O; Deiva K; De Sèze J; Fujihara K; Jacob A; Kim HJ; Kleiter I; Lassmann H; Leite MI; Linington C; Meinl E; Palace J; Paul F; Petzold A; Pittock S; Reindl M; Sato DK; Selmaj K; Siva A; Stankoff B; Tintore M; Traboulsee A; Waters P; Waubant E; Weinshenker B; Derfuss T; Vukusic S; Hemmer B
Lancet Neurol; 2021 Sep; 20(9):762-772. PubMed ID: 34418402
[TBL] [Abstract][Full Text] [Related]
39. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
[TBL] [Abstract][Full Text] [Related]
40. The clinical value of the albumin quotient in patients with neuromyelitis optica spectrum disorder.
Chen B; Qin C; Tao R; Dong YJ; Ma X; Chen M; Wu LJ; Bu BT; Tian DS
Mult Scler Relat Disord; 2020 Feb; 38():101880. PubMed ID: 31812873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
